Psilocybin-Assisted Therapy for Physician Well-Being and Burnout
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age21-70
SponsorUniversity of California, San Diego
About this trial
Through an open-label study involving a small group of UCSD physicians experiencing burnout, the investigators will evaluate the feasibility, safety, and preliminary effectiveness of PAT to reduce burnout symptoms.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Faculty physician, aged 21-70. Volunteer faculty are not included
Meets criteria for physician burnout
Experiencing symptoms of burnout for >6 months
Able to complete all required study visits
Disqualifiers
Previous inpatient psychiatric hospitalization(s)
Previously diagnosed with a psychotic disorder (schizophrenia, schizoaffective disorder, or other psychotic spectrum disorder), bipolar spectrum disorder, personality disorder (borderline personality disorder, antisocial personality disorder, or other severe personality disorders), any severe psychiatric disorder.
Exhibiting elevated suicide risk
First degree family history of psychosis or bipolar disorder
Trial design
Design model
Parallel
Treatments tested in this trial
Psilocybin, [3-[2-(dimethylamino)ethyl]-1H-indol-4-yl] dihydrogen phosphate
Drug25 mg, single dose of psilocybin
Real-time Biofeedback
DeviceReal-time visual biofeedback signal derived from multimodal dyadic synchrony measures (e.g., EEG, autonomic physiology, facial expression, speech) presented to the therapist during therapy sessions to inform delivery of psychotherapy.
Treatment groups
30 Participants
are divided into 2 treatment groupsGroup A: Psilocybin-Assisted Therapy with BiofeedbackExperimental treatment 2 interventions
Group B: Psilocybin-Assisted Therapy without BiofeedbackActive comparator 1 intervention
Trial outcomes
Primary outcomes
1
Stanford Professional Fulfillment Index (PFI)
Assessment used to determine degree/severity of burnout.
Time frame
From enrollment until end of study at 12 week follow-up.Sponsors and contacts
Click on the lead sponsor to view all of their trials.
University of California, San Diego
Lead sponsor
Advanced Research Projects Agency for Health (ARPA-H)
Collaborator
Source ClinicalTrials.gov